Biosimilar insulins: guidance for data interpretation by clinicians and users-Reference-Cited by-同舟云学术

Biosimilar insulins: guidance for data interpretation by clinicians and users

Published:2015-07 Issue:10 Volume:17 Page:911-918
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Heinemann L.¹,Home P. D.²,Hompesch M.³

Affiliation:

1. Science & Co Düsseldorf Germany

2. Institute of Cellular Medicine ‐ Diabetes, The Medical School Newcastle University Newcastle upon Tyne UK

3. Profil Institute for Clinical Research San Diego CA USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12491

Reference35 articles.

1. Eli Lilly and Company.European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe.2014. Available from URL:www.lilly.mediaroom.com/index.php?s=9042&item=137348. Accessed 31 December 2014.

2. European Medicines Agency.EPAR summary for the public Abrasia insulin glargine.2014. Available from URL:ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002835/WC500175383.pdf. Accessed 31 December 2014.

3. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins

4. Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?

5. IMS Health.Shaping the biosimilars opportunity.2011. Available from URL:www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf. Accessed 31 December 2014.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study;Diabetes, Obesity and Metabolism;2024-04

2. Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials;Journal of Diabetes Science and Technology;2022-07-11

3. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2021-01

4. Update on Diabetes Medical Management: Epidemiology and Treatment;Behavioral Diabetes;2020

5. Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins;Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease;2019